Respiri - Focus on cost optimisation
To support an optimal roll-out of its US commercialisation strategy for its wheezo device, Respiri recently announced several cost-saving initiatives, the latest being a reduction in the CEO’s and executive chairman’s FY23 cash compensation by a combined A$180k. In exchange, the company will offer bonus/milestone payments, contingent on achieving certain patient recruitment targets (elucidated below). This announcement follows management’s recent establishment of a Centre of Digital Innovation Excellence in the Philippines to drive efficiencies with a lower cost footprint (estimated to reduce IT costs by c A$700k, along with a 30% improvement in productivity). All cost savings will be redirected towards onboarding patients in the US. We also note that Respiri recently raised A$1.6m through share placements to support its US roll-out plans (40m shares to be issued on 7 October versus 23 September previously). Our valuation remains unchanged at A$0.24 per share.Respiri is engaged in the research, development and commercialization of medical devices, and the development of mobile health applications. Co.'s reportable segments are Australia and Israel.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.